10306 studies found for:    NCI
Show Display Options
Rank Status Study
21 Active, not recruiting Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: high performance liquid chromatography;   Genetic: microarray analysis;   Genetic: RNA analysis;   Other: mass spectrometry;   Genetic: DNA methylation analysis;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry
22 Terminated
Has Results
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: obatoclax mesylate;   Drug: bortezomib;   Other: laboratory biomarker analysis
23 Recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Childhood Low-grade Cerebellar Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Mixed Glioma;   Childhood Pilocytic Astrocytoma;   Neurofibromatosis Type 1;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Oligodendroglioma;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: selumetinib;   Other: laboratory biomarker analysis;   Other: pharmacological study
24 Active, not recruiting Fulvestrant With or Without Bortezomib in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage III Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: fulvestrant;   Drug: bortezomib;   Other: laboratory biomarker analysis
25 Terminated Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Blastic Phase Chronic Myelogenous Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: entinostat;   Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
26 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
27 Active, not recruiting
Has Results
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
28 Recruiting Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Conditions: Childhood Mixed Glioma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Fibrillary Astrocytoma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Glioblastoma;   Untreated Childhood Gliosarcoma
Interventions: Drug: veliparib;   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Other: pharmacological study;   Other: laboratory biomarker analysis
29 Active, not recruiting Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: tivantinib;   Other: laboratory biomarker analysis
30 Not yet recruiting Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: navitoclax;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
31 Completed FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Intervention: Drug: FR901228
32 Completed Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: prednisone;   Drug: vincristine sulfate;   Drug: daunorubicin hydrochloride;   Drug: asparaginase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: leucovorin calcium;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: thioguanine;   Radiation: radiation therapy;   Drug: nelarabine;   Drug: pegaspargase;   Other: pharmacological study;   Other: laboratory biomarker analysis
33 Completed Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Retinoblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: becatecarin
34 Completed
Has Results
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery
35 Completed Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
36 Completed Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: ixabepilone;   Other: laboratory biomarker analysis
37 Completed
Has Results
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: O6-benzylguanine;   Drug: temozolomide
38 Completed
Has Results
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
Conditions: Adult Angiosarcoma;   Adult Epithelioid Sarcoma;   Adult Leiomyosarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Neurofibrosarcoma;   Adult Synovial Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma;   Uterine Carcinosarcoma;   Uterine Leiomyosarcoma
Intervention: Drug: sorafenib tosylate
39 Completed Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Drug: tandutinib;   Other: laboratory biomarker analysis
40 Completed
Has Results
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: alvocidib;   Drug: mitoxantrone hydrochloride;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years